Document Detail

Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib.
MedLine Citation:
PMID:  21767516     Owner:  NLM     Status:  MEDLINE    
Patients with acute myeloid leukemia (AML) and internal tandem duplication of FMS-like tyrosine kinase receptor-3 gene (FLT3-ITD) mutation have poor prognoses and are often treated with allogeneic hematopoietic stem cell transplantation (HSCT). Sorafenib, an inhibitor of multiple kinases including FLT3, has shown promising activity in FLT3-ITD-positive AML. We treated 16 patients with FLT3-ITD-positive AML who relapsed after HSCT with sorafenib alone (n = 8) or in combination with cytotoxic chemotherapy (n = 8). The number of circulating blasts decreased in 80% of cases, but none of the patients achieved complete remission (CR); 3 achieved partial remission. Two patients were bridged to a second transplantation but both relapsed within 3 months of the transplantation. Median overall survival (OS) was 83 days, with none surviving more than a year. Sorafenib is not effective in the treatment of FLT3-ITD-positive AML relapsing after HSCT. Preventive strategies after HSCT may be more suitable for these high-risk patients.
Manish Sharma; Farhad Ravandi; Ulas Darda Bayraktar; Alexandre Chiattone; Qaiser Bashir; Sergio Giralt; Julianne Chen; Muzaffar Qazilbash; Partow Kebriaei; Marina Konopleva; Michael Andreeff; Jorge Cortes; Deborah McCue; Hagop Kantarjian; Richard E Champlin; Marcos de Lima
Related Documents :
8086676 - Necrotizing enterocolitis--multisystem organ failure of the newborn?
21960946 - Acute renal failure in association with community-acquired clostridium difficile infect...
22231466 - Enteral nutrition: a first option for nutritional support of children following allo-sct?
21661426 - The influence of immunosuppression switching in liver function in adult hepatic transpl...
11972216 - Laparoscopic fenestration of posttransplant lymphoceles.
22473466 - Head and neck cancer in transplant recipients.
Publication Detail:
Type:  Journal Article     Date:  2011-07-20
Journal Detail:
Title:  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation     Volume:  17     ISSN:  1523-6536     ISO Abbreviation:  Biol. Blood Marrow Transplant.     Publication Date:  2011 Dec 
Date Detail:
Created Date:  2011-11-18     Completed Date:  2012-05-31     Revised Date:  2014-07-04    
Medline Journal Info:
Nlm Unique ID:  9600628     Medline TA:  Biol Blood Marrow Transplant     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1874-7     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Benzenesulfonates / administration & dosage,  therapeutic use*
Combined Modality Therapy
Hematopoietic Stem Cell Transplantation / methods*
Leukemia, Myeloid, Acute / drug therapy*,  enzymology,  genetics,  surgery*
Middle Aged
Niacinamide / analogs & derivatives
Phenylurea Compounds
Protein Kinase Inhibitors / therapeutic use
Pyridines / administration & dosage,  therapeutic use*
Retrospective Studies
Transplantation, Homologous / methods*
Young Adult
fms-Like Tyrosine Kinase 3 / antagonists & inhibitors,  biosynthesis*,  genetics
Grant Support
P01 CA055164/CA/NCI NIH HHS; P30 CA016672/CA/NCI NIH HHS
Reg. No./Substance:
0/Antineoplastic Agents; 0/Benzenesulfonates; 0/Phenylurea Compounds; 0/Protein Kinase Inhibitors; 0/Pyridines; 0/sorafenib; 25X51I8RD4/Niacinamide; EC protein, human; EC Tyrosine Kinase 3

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Long-term outcome of patients with metastatic breast cancer treated with high-dose chemotherapy and ...
Next Document:  Subcellular heterogeneity of sodium current properties in adult cardiac ventricular myocytes.